Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bendroflumethiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bendroflumethiazide SCHEMBL4427489 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumethiazide SCHEMBL44537 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumethiazide SCHEMBL26016 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumetazide SCHEMBL29742733 | 0.93 | ALDH1A1 (0.86) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumethiazide SCHEMBL28086384 | 0.92 | LMNA (0.85) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| SCHEMBL13823288 | 0.87 | ALDH1A1 (0.76) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumethiazide SCHEMBL16222867 | 0.86 | ALDH1A1 (0.73) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| SCHEMBL19167246 | 0.84 | ALDH1A1 (0.73) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumethiazide SCHEMBL10380009 | 0.84 | ALDH1A1 (0.71) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| SCHEMBL13815372 | 0.84 | ALDH1A1 (0.72) | ALDH1A1LMNAKDM4ECYP3A4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025050228-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2025-03-13 | — | — | WO | claimed |
| CN-109358138-A | A kind of efficient liquid-phase chromatography method separating (R)-bendroflumethiazide and (S)-bendroflumethiazide | 南京盖斯夫医药科技有限公司 | 2019-02-19 | — | — | CN | claimed |
| CN-109342612-A | A kind of HPLC method separating (R)-bendroflumethiazide and (S)-bendroflumethiazide | 南京盖斯夫医药科技有限公司 | 2019-02-15 | — | — | CN | claimed |
| WO-2014026261-A1 | SOLID ORAL PHARMACEUTICAL PREPARATION FOR PREVENTING CEREBROVASCULAR AND HEART DISEASES, AND TABLET | HYPERMARCAS S.A. (BR) | 2014-02-20 | — | — | WO | claimed |
| WO-2013159166-A1 | PHARMACEUTICAL ORAL DOSAGE FORM FOR PREVENTING VASCULAR DISEASES, TABLET AS PHARMACEUTICAL DOSAGE FORM AND GELATIN CAPSULE AS PHARMACEUTICAL DOSAGE FORM | HYPERMARCAS S.A. (BR) | 2013-10-31 | — | — | WO | claimed |
| WO-2010069090-A2 | PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2010-06-24 | — | — | WO | claimed |
| WO-2025050228-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2025-03-13 | — | — | WO | disclosed |
| CN-109444292-A | A kind of HPLC method separating (R)-methychlothiazide and (S)-methychlothiazide | 南京盖斯夫医药科技有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-109358138-A | A kind of efficient liquid-phase chromatography method separating (R)-bendroflumethiazide and (S)-bendroflumethiazide | 南京盖斯夫医药科技有限公司 | 2019-02-19 | — | — | CN | disclosed |
| CN-109358139-A | A kind of efficient liquid-phase chromatography method separating (R)-methychlothiazide and (S)-methychlothiazide | 南京盖斯夫医药科技有限公司 | 2019-02-19 | — | — | CN | disclosed |
| CN-109358138-A | A kind of efficient liquid-phase chromatography method separating (R)-bendroflumethiazide and (S)-bendroflumethiazide | 南京盖斯夫医药科技有限公司 | 2019-02-19 | — | — | CN | disclosed |
| CN-109358138-A | A kind of efficient liquid-phase chromatography method separating (R)-bendroflumethiazide and (S)-bendroflumethiazide | 南京盖斯夫医药科技有限公司 | 2019-02-19 | — | — | CN | disclosed |
| CN-109342612-A | A kind of HPLC method separating (R)-bendroflumethiazide and (S)-bendroflumethiazide | 南京盖斯夫医药科技有限公司 | 2019-02-15 | — | — | CN | disclosed |
| CN-109342612-A | A kind of HPLC method separating (R)-bendroflumethiazide and (S)-bendroflumethiazide | 南京盖斯夫医药科技有限公司 | 2019-02-15 | — | — | CN | disclosed |
| CN-109342612-A | A kind of HPLC method separating (R)-bendroflumethiazide and (S)-bendroflumethiazide | 南京盖斯夫医药科技有限公司 | 2019-02-15 | — | — | CN | disclosed |
| WO-2014140402-A1 | USE OF DERIVATIVES WITH C-O-P BONDS IN PATIENTS WITH RENAL FAILURE | LABORATORIS SANIFIT, S. L. (ES) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013159166-A1 | PHARMACEUTICAL ORAL DOSAGE FORM FOR PREVENTING VASCULAR DISEASES, TABLET AS PHARMACEUTICAL DOSAGE FORM AND GELATIN CAPSULE AS PHARMACEUTICAL DOSAGE FORM | HYPERMARCAS S.A. (BR) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013149355-A1 | USE OF ANGIOTENSIN 1-9 IN COMBINATION IN ORDER TO PREVENT ARTERIAL HYPERTENSION | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2013-10-10 | — | — | WO | disclosed |
| WO-2010069090-A2 | PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2010-06-24 | — | — | WO | disclosed |